SPY424.55-0.72 -0.17%
DIA343.46-0.84 -0.24%
IXIC14,068.38-105.77 -0.75%

Sanofi Agrees to Supply Alemtuzumab Antibody for Cellectis Trials

05/12/2021 01:35

05:27 AM EDT, 05/12/2021 (MT Newswires) -- Sanofi (SNY) has agreed to supply the alemtuzumab antibody for use in Cellectis' (CLLS) clinical trials, the companies said late Tuesday.

In the Cellectis-sponsored trials, alemtuzumab is currently used as part of treatment regimens for acute lymphocytic leukemia and acute myeloid leukemia.

The companies may also enter into discussions to execute a commercial supply of alemtuzumab under pre-agreed financial conditions, according to the statement.

Price: 15.88, Change: +0.88, Percent Change: +5.87